MeiraGTx Holdings plc (MGTX) Current Ratio
- Current ratio · latest quarter: Value 3.76×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.76× | Current assets / current liabilities. $218.35M ÷ $58.10M ≈ 3.76× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 218.35M USD | Assets, Current |
| Current obligations | 58.10M USD | Liabilities, Current |
| Cash and equivalents | 143.17M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | 11.67M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $218.35M | $58.10M | $143.17M | (m) | (m) | (m) | $11.67M | (m) | 3.76× |
| 2026-03-31 | $96.20M | $176.13M | $71.54M | (m) | $3.26M | (m) | $16.66M | (m) | 0.55× |
| 2025-12-31 | $91.76M | $122.56M | $65.93M | (m) | (m) | (m) | $10.07M | (m) | 0.75× |
| 2025-09-30 | $34.17M | $152.92M | $14.84M | (m) | $2.81M | (m) | $21.54M | (m) | 0.22× |
| 2025-06-30 | $47.08M | $53.44M | $32.17M | (m) | $2.32M | $314.00K | $25.59M | (m) | 0.88× |
| 2025-03-31 | $79.89M | $52.37M | $66.52M | (m) | $734.00K | $607.00K | $20.29M | (m) | 1.53× |
| 2024-12-31 | $123.52M | $60.78M | $103.66M | (m) | $707.00K | $385.00K | $23.59M | (m) | 2.03× |
| 2024-09-30 | $139.05M | $59.42M | $122.87M | (m) | $3.28M | (m) | $29.50M | (m) | 2.34× |
| 2024-06-30 | $110.77M | $47.01M | $99.97M | (m) | $1.63M | (m) | $21.40M | (m) | 2.36× |
| 2024-03-31 | $149.30M | $47.54M | $119.21M | (m) | $10.91M | (m) | $21.22M | (m) | 3.14× |
| 2023-12-31 | $159.62M | $67.08M | $129.57M | (m) | $10.14M | (m) | $16.04M | (m) | 2.38× |
| 2023-09-30 | $103.53M | $63.51M | $63.37M | (m) | $22.40M | (m) | $20.77M | (m) | 1.63× |
| 2023-06-30 | $143.14M | $71.80M | $92.77M | (m) | $32.69M | (m) | $28.50M | (m) | 1.99× |
| 2023-03-31 | $121.48M | $81.10M | $68.78M | (m) | (m) | (m) | $29.75M | (m) | 1.50× |
| 2022-12-31 | $154.34M | $82.07M | $115.52M | (m) | $21.33M | (m) | $16.62M | (m) | 1.88× |
| 2022-09-30 | $155.04M | $72.36M | $114.71M | (m) | (m) | (m) | $21.69M | (m) | 2.14× |
| 2022-06-30 | $104.41M | $67.50M | $72.11M | (m) | (m) | (m) | $18.11M | (m) | 1.55× |
| 2022-03-31 | $142.93M | $65.50M | $113.78M | (m) | (m) | (m) | $18.50M | (m) | 2.18× |
| 2021-12-31 | $183.24M | $68.13M | $137.70M | (m) | (m) | (m) | $15.35M | (m) | 2.69× |
| 2021-09-30 | $176.93M | $59.63M | $143.63M | (m) | (m) | (m) | $11.42M | (m) | 2.97× |
| 2021-06-30 | $207.04M | $57.25M | $172.56M | (m) | (m) | (m) | $11.64M | (m) | 3.62× |
| 2021-03-31 | $230.13M | $53.52M | $199.41M | (m) | (m) | (m) | $7.90M | (m) | 4.30× |
| 2020-12-31 | $272.58M | $54.15M | $209.52M | (m) | (m) | (m) | $7.13M | (m) | 5.03× |
| 2020-09-30 | $217.88M | $46.61M | $179.08M | (m) | (m) | (m) | $5.20M | (m) | 4.67× |
| 2020-06-30 | $235.21M | $46.72M | $194.81M | (m) | (m) | (m) | $3.09M | (m) | 5.03× |
| 2020-03-31 | $251.01M | $43.03M | $210.41M | (m) | (m) | (m) | $7.29M | (m) | 5.83× |
| 2019-12-31 | $268.98M | $49.20M | $227.23M | (m) | (m) | (m) | $3.76M | (m) | 5.47× |
| 2019-09-30 | $271.09M | $39.29M | $253.33M | (m) | (m) | (m) | $3.80M | (m) | 6.90× |
| 2019-06-30 | $212.88M | $40.79M | $204.27M | (m) | (m) | (m) | $3.23M | (m) | 5.22× |
| 2019-03-31 | $231.16M | $33.20M | $227.28M | (m) | (m) | (m) | $3.38M | (m) | 6.96× |
| 2018-12-31 | $74.65M | $15.50M | $68.08M | (m) | (m) | (m) | $3.04M | (m) | 4.82× |
| 2018-09-30 | $91.31M | $8.49M | $88.56M | (m) | (m) | (m) | $2.42M | (m) | 10.76× |
| 2018-06-30 | $103.99M | $8.78M | $102.06M | (m) | (m) | (m) | $3.46M | (m) | 11.84× |
| 2017-12-31 | $11.48M | $21.40M | $8.55M | (m) | (m) | (m) | $7.06M | (m) | 0.54× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |